Sarepta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06606340
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06597656
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06270719
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06246513
- Locations
- 🇬🇧
Newcastle University, Newcastle upon Tyne, United Kingdom
🇺🇸University of California, San Diego-Altman Clinical and Translational Research Institute, La Jolla, California, United States
🇺🇸Nationwide Childrens Hospital, Columbus, Ohio, United States
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06241950
- Locations
- 🇪🇸
Hospital Sant Joan de Déu, Barcelona, Spain
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05967351
- Locations
- 🇺🇸
University of Utah Health, Salt Lake City, Utah, United States
🇬🇧Great Ormond Street Hospital For Children NHS Foundation Trust, London, Greater London, United Kingdom
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05906251
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT05881408
- Locations
- 🇸🇪
Karolinska Universitetssjukhuset/Astrid Lindgrens Barnsjukhus, Barnneurologen, Solna, Sweden
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05876780
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05096221
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸UC San Diego Altman Clinical and Translational Research Institute, La Jolla, California, United States